SEC Tracker
Get the app
IRWD · XBRL financial data

Ironwood Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (IRWD's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers11411875949291418512248107113
Research and development3336*26303025*27232222*2222
Selling, general and administrative3639*38373634*24172219*1211
Operating income (loss)4038*11252631*(29)45757*7379
Interest expense108*7799*8888*97
Other income (expense)—————year only0000*00
Income tax expense (benefit)1832*9201422*114283*2422
Net income (loss)15(1)(4)(1)42(37)2440(2)4151
Earnings per share, basic USD per share0.10(0.01)(0.03)(0.01)0.020.01(0.23)0.150.25(0.01)0.250.31
Earnings per share, diluted USD per share0.09(0.01)(0.03)(0.01)0.020.01(0.23)0.140.23(0.01)0.240.31
Weighted average shares, basic millions of shares156156*158159160160*161162162162*163164
Weighted average shares, diluted millions of shares187—158159160163*161177178136*167167

Balance sheet

CSV

Fiscal quarters (IRWD's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents1109212210688891089314021522079
Accounts receivable12512972587682408612047106113
Prepaid and other current assets1812151514121213131267
Total current assets254233208178179182161192274274332199
Property and equipment, net665554444333
Right-of-use asset131312121111111010998
Total assets524471439396390351327343396397435285
Accounts payable586332612331
Total current liabilities2812762524649394823324324223633
Lease liability, non-current1515141313121211101099
Total liabilities—————————659—447
Accumulated deficit(1,698)(1,699)(1,703)(1,704)(1,700)(1,698)(1,735)(1,712)(1,671)(1,674)(1,633)(1,582)
Total stockholders' equity(323)(346)(331)(322)(311)(301)(334)(308)(264)(262)(217)(162)
Total liabilities and equity524471439396390351327343396397435285
Common shares outstanding (cover page) millions of shares156157159160160162162162163163165165

Cash flows

CSV

Fiscal quarters (IRWD's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)15(1)(4)(1)42(37)2440(2)4151
Stock-based compensation8*9*89*8*5*55*4*4*43*
Depreciation and amortization—year only———year only———year only——
Net cash from operating activities32*36*4533*10*15*20(15)*48*75*558*
Purchases of property and equipment0*0*00*0*0*00*0*(0)*——
Net cash from investing activities(23)*(4)*(0)(0)*(0)*0*(0)(0)*(0)*0*——
Net cash from financing activities(75)*(51)*(16)(49)*(27)*(15)*00*0*0*——
Net change in cash(65)*(19)*29(16)*(17)*0*20(16)*48*75*5(141)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Ironwood Pharmaceuticals7911358*165.2M— 10-QJun 30, 2026
Vaxart51272.8*242.8M— 10-QJun 30, 2026
Achieve Life Sciences48not reported(11)*102.9M17.4 quarters 10-QJun 30, 2026
Fennec Pharmaceuticals41180.1*35.1M— 10-QJun 30, 2026
Milestone Pharmaceuticals1700.6(23)*124.5M7.5 quarters 10-QJun 30, 2026
Atossa Therapeutics26not reported(9.6)*10.0M2.7 quarters 10-QJun 30, 2026
Assembly Biosciences32not reported(15)*20.4M20.7 quarters 10-QJun 30, 2026
Cartesian Therapeutics1480(21)*30.3M7.0 quarters 10-QJun 30, 2026
Galectin Therapeutics13not reported(2.4)*100.8M5.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.